

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEP MENT OF COMMERCE
United States Patent any Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/673,490	12/11/2000	Roger Desmond Drinkwater	13922	6804	
7:	590 12/18/2002				
	Aurphy & Presser		EXAMI	EXAMINER	
400 Garden City Plaza Garder City, NY 11530			BUGAISKY, C	GABRIELE E	
			ART UNIT	PAPER NUMBER	
			1653	19	
			DATE MAILED: 12/18/2002	1 /	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Office Action Summany	09/673,490	DRINKWATER ET AL.			
Office Action Summary	Examiner	Art Unit			
The MAILING DATE of this communication and	Gabriele E. BUGAISKY	1653			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1) Responsive to communication(s) filed on					
2a) ☐ This action is FINAL . 2b) ☐ This	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims					
4)⊠ Claim(s) <u>1-19</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)☐ Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8)⊠ Claim(s) <u>1019</u> are subject to restriction and/or e	election requirement.				
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) \square The translation of the foreign language provisional application has been received. 15) \square Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) S Patent and Trademot Office S Patent and Trademot Office	5) Notice of Informal F	r (PTO-413) Paper No(s) Patent Application (PTO-152)			

8

Application/Control Number: 09/673,490

Art Unit: 1653

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-9 and 14-19, drawn to conotoxin peptides, compositions containing them and methods of their use.

Group II, claim(s) 10-11 and 13, drawn to nucleic acids encoding conotoxins.

Group III, claim(s) 12, drawn to antibodies directed against conotoxins.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the general concept is conotoxins comprising the sequence SGTVGR, or such a sequence which has undergone one or more amino acid substitutions or side chain modifications. Since such sequence which have undergone one or more amino acid substitutions are known in the art (E.g., conotoxins MVIIA, MVIIBGVIA, GVIIA, etc., , the general concept cannot be considered a special technical feature. PCT Rules 13.1-13.2 do not provide for multiple products.

This application contains further claims directed to the following patentably distinct compounds, (which have different primary structures) of the claimed invention: specific peptides of SEQ ID NO: 5-32, specific nucleic acids encoding these peptides and antibodies directed against each of these peptides. Applicant is required under 35 U.S.C. 121 to elect a single disclosed compound for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. The Examiner will examine an identified protoxin

Application/Control Number: 09/673,490

Art Unit: 1653

along with the mature form. Currently, claims 1-4, 8-9 and 14-19 of Group I and all claims of II-III are generic.

Applicant is advised that a reply to this requirement must include an identification of the peptide, nucleic acid or antibody that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election

This further election requirement is not be construed as a species election, as these compounds do not share a common primary structure and appear to be patentably distinct.

Should applicant traverse on the ground that these different compounds are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Application/Control Number: 09/673,490 Page 4

Art Unit: 1653

application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gabriele E. BUGAISKY whose telephone number is (703)308-4201. The examiner can normally be reached on 8:15 AM- 2 PM, Tu & Th, 8:15 AM-1:30 PM, We & Fr.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher SF Low can be reached on (703) 308-2923. The fax phone numbers for the organization where this application or proceeding is assigned are 703 308-4242 for regular communications and 703 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 708 308-0196.

Gabriele E. BUGAISI Primary Examiner

Art Unit 1653

December 16, 2002

GABRIELLE BUGAISKY PRIMARY EXAMINER